Home  | About mdi |  Services  | Industries | News & Information | Partners | Contact| Site Map

June 27- July 3

June 27^th: U.S. Food and Drug Administration Clears for Marketing Integrated Electroanatomical Navigation System for Diagnosis and Treatment of Abnormal Heart Rhythms

Millions of people suffering from cardiac arrhythmias, also known as abnormal heart rhythms, can look forward to advanced care with another new offering from medical device maker, Biosense Webster, Inc. The U.S. Food and Drug Administration (FDA) today cleared for marketing under a 510K application an innovative technology designed to help physicians diagnose and plan treatment for patients with this condition.

The Carto(TM) RMT V8 System from Biosense Webster, Inc. and the Niobe® Magnetic Navigation System from Stereotaxis, Inc. provide electrophysiologists (doctors specializing in the heart's electrical system) with automated, cutting-edge, 3-D mapping and navigation tools, and a magnetic steering platform.

Among the many enhanced offerings of the system integration is real-time feedback in guiding the catheter to the target, as well as simultaneous display of the NaviStar® RMT Catheter on Carto(TM) RMT System and Niobe® Screens and bi-directional communication between the two technologies. The new system and catheter provide greater efficiency and better signal resolution, reduced redundancy in data entry and increased reproducibility through automation.

Biosense Webster, Inc., a leader in the development of advanced diagnostic, therapeutic and mapping tools for electrophysiologists, is the only company to offer products integrated with the Stereotaxis system, which enables electrophysiologists to steer a catheter remotely, map the electrical activity of the heart and ablate targeted areas with potentially less trauma due to the soft, flexible catheter.
 

June 28^th: Angiotech Pharmaceuticals Completes Acquisition of Quill Medical, Inc.

Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, today announced that it has completed its acquisition of privately held Quill Medical, Inc. ("Quill") - including all of its technology and intellectual property - for US $40 million in cash plus certain future contingent payments based on product revenues, as previously announced on May 25, 2006.

In October 2004, Angiotech's Surgical Specialties division and Quill entered into an exclusive manufacturing and distribution agreement for the Contour Threads(TM) product line to be used in minimally-invasive aesthetic and cosmetic surgery. Unlike conventional sutures which are smooth, the Contour Threads products have tiny teeth-like barbs or cogs along the surface. Once inserted under the skin, these self-anchoring sutures hold tissue in place to suspend sagging tissue or close wounds.

With the completion of the previously announced acquisition of Quill, Angiotech now fully owns the rights to develop novel applications of the Contour Threads product line in a variety of aesthetic markets as well as other large, non-aesthetic markets where sutures are commonly used, such as wound closure and tendon repair for orthopaedic applications.

Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company with 14 facilities in 6 countries and over 1,500 dedicated employees. Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury.
 

June 30^th: Integra LifeSciences Announces Agreement to Acquire Kinetikos Medical, Inc.

Integra LifeSciences Holdings Corporation announced today that it has agreed to acquire the shares of Kinetikos Medical, Inc. (``KMI'') for approximately $40 million in cash, subject to certain adjustments, including future payments based on the performance of the KMI business after the acquisition.

KMI, based in Carlsbad, California, is a leading developer and manufacturer of innovative orthopedic implants and surgical devices for small bone and joint procedures involving the foot, ankle, hand, wrist and elbow. KMI generated revenues of $11.4 million for the twelve months ended March 31, 2006.

KMI has an experienced senior management team with a proven track record in the orthopedics device industry. Upon closing, the management of KMI will join the leadership team at Integra.

KMI currently markets products that address both the trauma and reconstructive segments of the extremities market. KMI's reconstructive products are largely focused on treating deformities and arthritis in small joints of the upper and lower extremities, while its trauma products are focused on the treatment of fractures of small bones most commonly found in the extremities.

This acquisition is expected to be neutral to Integra's adjusted earnings, which exclude costs related to the fair value purchase accounting for acquired inventory, restructuring and integration charges and the impact of estimated share-based compensation expense, for the remainder of 2006 and accretive to Integra's earnings thereafter. Integra LifeSciences Holdings Corporation is a diversified medical technology company that develops, manufactures, and markets medical devices for use in a variety of applications.

Home  | About mdi |  Services  | Industries | News & Information | Partners | Contact| Site Map